Preclinical Efficacy Evaluation of Agonistic CD137 Therapeutic Antibodies in Human CD137 Knock-In Mouse Models (HuGEMM™)
Xuesong Huang, Gang Chen*, Lei Zheng, Annie An, Jean-Pierre Wery, Jay Liu*, Xin Dong*, Qian Shi, and Davy Xuesong Ouyang
*Nanjing Galaxy Biopharmaceutical Co. Ltd., Nanjing, China
PD-1/PD-L1 checkpoint inhibitors have achieved huge clinical success (and drug approval) across a range of cancer types. However, overall response rates to these agents remains low.
Efforts are now focused on combination strategies which could improve T cell tumor killing activities. For example, agonist CD137 antibodies could be used in combination with anti-PD-1/PD-L1 agents to both prime and activate T cells.
Research into these antibodies is being hindered by a lack of preclinical animal models for the in vivo assessment of human-specific therapeutics. CrownBio has developed a range of humanized drug target immunocompetent models, including a CD137 model, to enable novel immunotherapy and combination evaluation.
Read this Poster to Discover:
- The development of a CD137 humanized model (with human CD137 within fully competent murine immunity) for evaluating CD137 mAb therapeutic efficacy
- Response to anti-CD137 antibody treatment, and combination therapy with CD137 + PD-1/PD-L1 antibodies, by MC38 tumors engrafted within this model
- Our range of available preclinical target humanized models, including PD-1, PD-L1, CTLA-4, and OX40, used to assess immunotherapeutic efficacy